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Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a global pathogen and an important but seldom
investigated cause of morbidity and mortality in lower and middle-income countries where it can place a major burden on
limited resources. Quantifying nosocomial transmission in resource-poor settings is difficult because molecular typing
methods are prohibitively expensive. Mechanistic statistical models can overcome this problem with minimal cost. We
analyse the transmission dynamics of MRSA in a hospital in south India using one such approach and provide conservative
estimates of the organism’s economic burden.
Methods and Findings: Fifty months of MRSA infection data were collected retrospectively from a Medical Intensive Care
Unit (MICU) in a tertiary hospital in Vellore, south India. Data were analysed using a previously described structured hidden
Markov model. Seventy-two patients developed MRSA infections and, of these, 49 (68%) died in the MICU. We estimated
that 4.2% (95%CI 1.0, 19.0) of patients were MRSA-positive when admitted, that there were 0.39 MRSA infections per
colonized patient month (0.06, 0.73), and that the ward-level reproduction number for MRSA was 0.42 (0.08, 2.04). Anti-
MRSA antibiotic treatment costs alone averaged $124/patient, over three times the monthly income of more than 40% of
the Indian population.
Conclusions: Our analysis of routine data provides the first estimate of the nosocomial transmission potential of MRSA in
India. The high levels of transmission estimated underline the need for cost-effective interventions to reduce MRSA
transmission in hospital settings in low and middle income countries.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the
most important nosocomial pathogens globally [1] and a major
cause of morbidity and mortality in high risk wards such as
intensive care units [2]. In some countries in Asia, MRSA accounts
for more than 70% of nosocomial S. aureus isolates [3,4]. However,
there remains a paucity of information about MRSA from most of
Asia [5]. In India, the few studies there have been suggest that the
prevalence of MRSA in hospitals is rising, and nationally MRSA is
now thought to account for about 30% of S. aureus infections in
hospital [6,7].
The spread of multi-drug resistant pathogens such as MRSA
poses a particularly serious threat in resource-poor settings where
associated morbidity and mortality may greatly exceed that seen in
resource rich settings [8]. Moreover, since antibiotics of last resort
such as vancomycin or linezolid may be prohibitively expensive in
many such settings, infections caused by such organisms can be
effectively untreatable [9]. However, epidemiological studies in
such resource-poor settings are largely lacking [10], and there have
been no documented attempts to quantify the nosocomial
transmission of MRSA in India. Quantifying such transmission
is important because in many parts of India there are high levels of
community-associated MRSA and establishing the sources and
sinks of MRSA infection is vital for setting infection control
priorities. In healthcare settings with limited resources, however,
extensive epidemiologic surveillance and molecular typing meth-
ods conventionally used to quantify the extent of hospital
transmission are prohibitively expensive. Novel statistical methods
can offer a highly economic alternative [11,12]. Such approaches,
which make use of mechanistic transmission models, have proved
useful in quantifying the extent of patient-to-patient transmission
and unravelling the transmission dynamics of such pathogens in
developed countries [13-16] and have been shown to yield similar
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this study, we describe the epidemiology of MRSA in a single high
risk medical intensive care unit (MICU) and use one such
mechanistic model to estimate key parameters for a model of
MRSA transmission among patients admitted to the unit using
routine data.
The statistical challenge in quantifying MRSA transmission
from routine infection data arises from the fact that only a
proportion of patients harbouring MRSA have symptomatic
infections; most are colonized asymptomatically and the epidemic
process can therefore only be partially observed. In the absence of
extensive (and expensive) whole ward surveillance and molecular
typing methods it is therefore difficult to know to what extent
increases in MRSA prevalence are the result of hospital
transmission as opposed to admissions of MRSA positive patients
from the community. Previous work has shown how this problem
can be overcome by making use of infection data to impute the
unobserved colonization dynamics, and we present data and
inferences based on these methods [12,19].
Methods
Study setting
The study setting was an eleven bedded medical intensive care
unit (MICU) within a 2,234 bedded tertiary care teaching hospital,
Vellore, south India. The staff-to-patient ratio was either 1:3 or 1:2
depending on the shift and bed occupancy was 100% (or very close
to 100%) throughout the study. The infection control policy
remained unchanged over the study period and recommended
hand hygiene before every patient contact using either alcohol hand
rub (SterilliumH) or surgical spirit BP which was kept at each
patient’s bedside. Hand hygiene compliance was not audited. No
screening to detect asymptomatic MRSA carriage was performed.
A single bed physically separated within the MICU was allotted for
isolation of known cases of MRSA infection. No other specific
interventions for the control of MRSA were in place throughout the
study period. For most of the study period, vancomycin was the first
choice antibiotic for treating MRSA infections provided patients
could affordit. Towards the end ofthe study period, teicoplaninwas
available in India and was preferred over vancomycin. This
research was approved by the Institutional Review Board of the
Christian Medical College, Vellore - 632 004, India.
Data
Data consisted of monthly totals of new MRSA infections among
patients admitted to the unit each month for a period of fifty
months, from January 2003 to February 2007. For those patients
identified with an MRSA infection , the date of admission, time
from admission (in days) to onset of symptoms that led to screening
for MRSA, days of hospitalization, status at discharge, admission
diagnosis, and cost of antibiotics for treating MRSA infection were
collected. Repeated infections on the same patient during the study
period were not included. Infection was classified as nosocomial if
the time from admission to onset of symptoms was greater than
48 hours. All data were collected retrospectively from the Hospital
Infection Control Committee office as obtained from the medical
microbiology alert notification and Medical Records department.
Patients with MRSA infections were retrospectively classified as
predisposing or non-predisposing to MRSA infection based on
admission diagnosis. Patients were considered to be predisposing if
they had at least one of a pre-specified list of systemic diseases
(such as diabetes, HIV infection, etc) or local conditions (such as
acute renal failure, subarachnoid haemorrhage, etc). Otherwise
they were considered non-disposing to MRSA infection [20].
Laboratory methods
S. aureus was identified from clinical isolates using the slide
coagulase test. If this was positive, presence of S. aureus was
confirmed using the tube coagulase test and mannite. Methicillin
resistance was detected using oxacillin disk diffusion, in accor-
dance with the Clinical and Laboratory Standards Institute.
Statistical analysis
Preliminary data analysis was performed to check for time
trends, seasonality, discontinuities, outliers and autocorrelation
using standard graphical methods.
A previously described structured hidden Markov model
(HMM) was fitted to the MRSA infection data [19]. This model
was used to account for the partially observed infection process, as
only the fraction of colonized patients who were symptomatically
infected is observed. The model allows the unobserved (or
‘‘hidden’’) number of patients asymptomatically colonized with
the organism at different time points to be estimated.
The term ‘structured’ signifies that the underlying Markov
model is constructed based on a mechanistic transmission model
where new infections are generated according to a mass action
process at a rate bCtSt/N, where b is a transmission parameter to
be estimated, N is the ward population size, Ct the (unknown)
number of patients colonized or infected with MRSA at time t (the
hidden state of the Markov chain), and St represents the remaining
MRSA-free patients. This transmission model corresponds to the
assumption that doubling the number of MRSA positive patients
on the ward (which corresponds to the colonization pressure),
would double the chance of a susceptible patient acquiring MRSA
in a small time interval. The model also allows estimation of a
probability, n, that each patient is carrying the organism when
admitted to the ward, and assumes a known discharge rate, m,
which has been directly estimated from data. The approach also
calculates the probability of each possible value of Ct at each time
point.
The number of observed infections at time t, Yt, is assumed to
depend (probabilistically) on the corresponding number colonized
at that time, Ct, according to a Poisson distribution with mean lCt:,
where the infection rate, l, is a parameter to be estimated. All
analyses were performed using R, a free open source language and
environment for statistical computing [21].
Results
A total of 72 MRSA infections were observed during the study
period, with an average of 1.44 cases per month. Of these, 56
(78%) were classified as nosocomial, 67% of infected patients were
male, the mean (SD) age was 48.8 (18.4) years and 92% of these
patients were mechanically ventilated. The median length of
hospital stay (inter-quartile range) of these infected patients was
15.5 (10–27) days, compared to 6 (2.25 – 12) days for all patients
combined. The average prevalence of MRSA infection in the
MICU over the whole study period (i.e., the percentage of MICU
patients known to have MRSA infections at some point during
their stay) was 2.1%.
Among patients with symptomatic MRSA infection, mortality
in the MICU was 68%. Mortality rates in the predisposing
(systemic or local) and non-predisposing groups were 79.2% and
40.9% respectively (odds ratio 5.49, 95% CI: 1.61, 19.31).
Transmission dynamics
The monthly count of MRSA infections in the MICU showed
no apparent trend and there were neither obvious outliers nor
discontinuities in the data. A seasonal subseries plot portraying the
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pattern of high or low number of infections with reference to any
particular month (figure 1(a)). Finally, the autocorrelogram, which
shows the degree of correlation between infections at each time
point and time points 0,1,2, … timesteps (lags) later, displayed a
gradual decrease of auto-correlation with increase in lags: at the
first three lags the autocorrelation was either significant at the 5%
level or very close to being so, and no significant autocorrelation
was detected at lags of six or more (figure 1(b)). Importantly, the
autocorrelogram showed no pattern that was consistent with
seasonal fluctuations. Thus, the time series was interpreted as
being stationary.
The matrix of transitions in the number of new infections
observed in consecutive months is displayed in table 1. The 0–0
Figure 1. Preliminary analyses, and output from the structured hidden Markov model. (a) seasonal subseries plot showing the number of
infections for each month of the year (horizontal lines represent the mean number of infections for the given month); (b) autocorrelogram, showing
the correlation between recorded monthly infections in data points separated by 0,1,2,3 months (lags); (c) Stationary distribution of number of
colonized patients; (d) Observed number of new infections and the expected number of new infections in each month estimated through the
structured hidden Markov model using the entire series of observations y1:::yn. Broken lines indicate central 95% bootstrap intervals obtained by
conditioning on the hidden state, and sampling this hidden state from a multinomial distribution using probabilities estimated by fitting the model
to data (see Figure 1 (e)) with 1000 bootstrap replicates; (e) Estimated conditional probabilities of different hidden states over time, Pr(Ctjy1:::yn).
doi:10.1371/journal.pone.0020604.g001
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that if there were no infections in one month, 50% of the time
there were also no infections during the next month. Estimates of
epidemiological parameters obtained with the transmission model
are summarized in table 2. The estimated transmission rate
parameter (^ b b) indicates that an MRSA positive patient in a fully
occupied ward otherwise free of MRSA would have to stay on
average 11.7 days (95% CI [2.4, 57.9]) before transmission of
MRSA to another patient occurred (calculated as the reciprocal of
the rate of new infections, bCSt/N). Assuming a mean length of
stay for all MRSA patients (detected and undetected) of 5 days, the
estimated ward-level reproduction number, RA (the mean number
of secondary MRSA cases generated by one case during a single
ward stay in an otherwise MRSA-free ward [19]) is 0.4 (95% CI
[0.1,2.1]. The infection rate (^ l l) estimate indicates that the model
predicts 0.4 (95% CI [0.1, 0.7]) symptomatic infections per
colonized patient month (Table 2). The Akaike Information
Criteria (AIC), which assesses goodness of model fit (the lower the
better) for the HMM is 80.08 (as compared to the simple and
widely-used Poisson model with AIC=152.3). This indicates a
greatly improved model fit using the dynamic HMM.
Figure 1 (c) shows the stationary (unconditional) probability
distribution of Ct, which can be interpreted as the mean daily
number of MRSA positive patients present on ward, and takes 12
possible values (the hidden states) from 0 to 11. This shows that the
most likely number of MRSA positive patients on the ward at one
time is 3–4, and 0 MRSA positive occurs with a probability of
0.061. Figure 1 (d) displays the observed number of new infections
in grey (solid lines) overlaid with the expected number of new
infections (given all observed data) fitted through the SIS HMM in
black. Broken lines indicate 95% bootstrap intervals for this
expectation obtained by conditioning on the hidden state, and
sampling this hidden state from a multinomial distribution using
probabilities estimated by fitting the model to data (these are
shown in Figure 1 (e)). The figure shows a good fit between the
observed and predicted number of infections providing graphical
evidence for an appropriate transmission model.
Costs
Besides the treatment cost for admission of the underlying
disease condition, the additional cost due to treatment of MRSA
infection was studied among patients with positive infection alone.
The median total cost of MRSA treatment (cost of antibiotics
alone) was 5,708.93 Indian Rupees (INR) (approximately $124),
with an inter-quartile range of INR (2041.5, 22239.75) (approx-
imately $45, $484). The median cost of treatment per day due to
MRSA infection was 788.27 INR (approximately $17) resulting
from additional antibiotic use to treat MRSA from the date of
diagnosis of MRSA infection to the date of discharge or death.
Discussion
Our analysis of a time series of MRSA infections provides
evidence that substantial transmission of MRSA is occurring in the
MICU, and yields estimates of basic transmission parameters.
Such estimates are of value not just for helping to identify infection
control priorities, but also for designing intervention studies and
providing model-based assessments of the likely effectiveness and
cost-effectiveness of different intervention policies. The results
suggest that concerted infection control interventions would have
the potential to substantially reduce the burden of MRSA disease
in this setting. While resources were lacking to verify our findings
using molecular typing methods, previous studies have found such
transmission models and molecular approaches to yield very
similar estimates [12]. We estimate a slightly higher incidence of
disease per MRSA patient day in this setting that that estimated
with the same approach from US data (0.39 versus 0.35 infections
per colonized patient month) [19]. For comparison a recent study
in 153 US veterans affairs hospitals [22], reported that pre-
intervention infection rates in ICUs averaged 1.64 per 100 patient
days. If we assume that 20% of the patient days were MRSA
positive (which seems reasonable given that 13% were positive on
admission) this corresponds to about 0.24 infections per month for
an MRSA colonized patient. While this is 38% lower than the
value we estimate in a resource-limited setting in India, we note
that substantially elevated infection rates are consistently found in
developing countries [23].
The stationary distribution reported in figure 1(d) shows the
estimated probability of there being 0,1,2,… MRSA positive
patients on the ward at one time. This shows that the estimated
proportion of time with no colonization or infected patients is low
(0.061). However, the data show that the proportion of months
with no observed symptomatic infections is quite large (0.32). This
discrepancy reflects a perpetuating hidden transmission and
colonization that can result in infections as and when vulnerable
patients come into contact with those who are colonized.
The costing data reported in this study suggest that the
economic consequences of MRSA in this setting may be
substantial. Based on 2005 figures, the median cost of anti-MRSA
antibiotic treatment alone exceeded the quarterly earnings of more
than 40% of the 1.2 billion people living in India [24]. The
median daily cost of anti-MRSA antibiotics per day, 788.27 INR
($17) also represents a substantial proportion of the mean daily
cost of MICU stay which was estimated from patient bills at
10,800 INR ($235). However, costing reported in this study must
be regarded as both preliminary and almost certainly conservative:
cost data amongst patients free of MRSA were not available for
Table 1. Observed transition in the number of new infections
in successive months.
Initial State Number of transitions to the following stages
01 2 3 4 5
0 85 2 1 0 0
1 31 4 3 0 0
2 15 1 2 1 0
3 41 2 0 1 1
4 00 1 1 0 0
5 00 1 0 0 0
doi:10.1371/journal.pone.0020604.t001





Estimates 95% Confidence Interval
Lower Upper
Transmission rate, ^ b b, (days
21) 0.094 0.019 0.459
Positives on admission (^ n n) 0.042 0.010 0.190
Infection rate ^ l l (months
21) 0.393 0.056 0.731
doi:10.1371/journal.pone.0020604.t002
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the antibiotic cost and do not include costing for additional length
stay resulting from MRSA infection. Some patients acquired more
than one infection i.e., infection from other organisms in addition
to MRSA and certain drugs that constituted for the antibiotic cost
in this analysis were prescribed for treating infections from more
than one organism and may not be specific to MRSA alone. On
the other hand, a few patients with multiple infections including
MRSA were not treated for MRSA and may have no additional
cost of treatment due to MRSA infection. Importantly, since very
few patients had medical insurance, ability to pay for expensive
antibiotics was a crucial factor in deciding whether or not patients
should receive a particular antibiotic or indeed any treatment at
all. This resulted in a wide range of treatment costs for MRSA
infections, and further highlights the importance of tackling
antimicrobial resistance in parts of the world where effective
antibiotics cannot be afforded by large parts of the population.
While this study does not rule out the possibility of substantial
community transmission of MRSA in southern India, and
although estimated transmission parameters are highly uncertain,
the best parameter estimates demonstrate that substantial ongoing
nosocomial transmission of MRSA is likely to be occurring in this
region. As with any model, the validity of the findings will depend
on the model assumptions which have been discussed at length
elsewhere [19]. Two particular limitations of our study (and of the
original hidden Markov model [19]) are the assumption of a
constant rate of ward discharge (implying an exponential length of
stay distribution) and the assumption that all autocorrelation is
generated by the epidemic process. We lacked sufficient data to
assess either assumption, though note that MICU length of stay
distributions are typically right skewed with very long tails and a
mode close to zero, and a constant rate of MICU discharge
therefore seems a reasonable simplification. Moreover, while other
factors affecting the transmission process cannot be ruled out, no
specific interventions to reduce MRSA were implemented over the
period when the data was collected. Thus, while we think these
assumptions are plausible, and previous studies have shown good
agreement with estimates of the same population parameters
derived using molecular data [12], and model predictions show
good agreement with our data, a major investment in microbi-
ology and patient screening would be required to provide further
validation for our findings.
Studies to investigate the control of MRSA and other healthcare
associated infections in resource poor settings are now considered
a priority by the World Health Organization [23]. In particular
there is a need to investigate the value of enhanced surveillance for
MRSA through patient screening, and to develop control policies
that are cost-effective in low and middle income countries.
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